These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

838 related articles for article (PubMed ID: 31548636)

  • 1. Targeting metabolic dysregulation for fibrosis therapy.
    Zhao X; Kwan JYY; Yip K; Liu PP; Liu FF
    Nat Rev Drug Discov; 2020 Jan; 19(1):57-75. PubMed ID: 31548636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver fibrosis: Direct antifibrotic agents and targeted therapies.
    Schuppan D; Ashfaq-Khan M; Yang AT; Kim YO
    Matrix Biol; 2018 Aug; 68-69():435-451. PubMed ID: 29656147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK1-Smad1/5 signaling pathway in fibrosis development: friend or foe?
    Muñoz-Félix JM; González-Núñez M; López-Novoa JM
    Cytokine Growth Factor Rev; 2013 Dec; 24(6):523-37. PubMed ID: 24055043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Fibrotic Diseases: Current Challenges in Fibrosis Research.
    Rosenbloom J; Macarak E; Piera-Velazquez S; Jimenez SA
    Methods Mol Biol; 2017; 1627():1-23. PubMed ID: 28836191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Potential of sGC Modulators for the Treatment of Age-Related Fibrosis: A Mini-Review.
    Sandner P; Berger P; Zenzmaier C
    Gerontology; 2017; 63(3):216-227. PubMed ID: 27784018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting fatty acid metabolism for fibrotic disorders.
    Hwang S; Chung KW
    Arch Pharm Res; 2021 Oct; 44(9-10):839-856. PubMed ID: 34664210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Organ fibrosis inhibited by blocking transforming growth factor-β signaling via peroxisome proliferator-activated receptor γ agonists.
    Deng YL; Xiong XZ; Cheng NS
    Hepatobiliary Pancreat Dis Int; 2012 Oct; 11(5):467-78. PubMed ID: 23060391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases.
    Adegunsoye A; Levy M; Oyenuga O
    Biomed Res Int; 2015; 2015():929170. PubMed ID: 26583148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unlocking the potential of tranilast: Targeting fibrotic signaling pathways for therapeutic benefit.
    Massoud G; Parish M; Hazimeh D; Moukarzel P; Singh B; Cayton Vaught KC; Segars J; Islam MS
    Int Immunopharmacol; 2024 Aug; 137():112423. PubMed ID: 38861914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring organ-specific features of fibrogenesis using murine precision-cut tissue slices.
    Bigaeva E; Gore E; Mutsaers HAM; Oosterhuis D; Kim YO; Schuppan D; Bank RA; Boersema M; Olinga P
    Biochim Biophys Acta Mol Basis Dis; 2020 Jan; 1866(1):165582. PubMed ID: 31676376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Transforming growth factor-beta and its receptors in scleroderma].
    QIAN H; ZHENG M
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Jul; 38(4):415-21. PubMed ID: 19693982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innovative antifibrotic therapies in systemic sclerosis.
    Beyer C; Distler O; Distler JH
    Curr Opin Rheumatol; 2012 May; 24(3):274-80. PubMed ID: 22450392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein degradation by the ubiquitin-proteasome pathway and organ fibrosis.
    Fukasawa H; Fujigaki Y; Yamamoto T; Hishida A; Kitagawa M
    Curr Med Chem; 2012; 19(6):893-900. PubMed ID: 22229415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the TGF-β signaling pathway for fibrosis therapy: a patent review (2015-2020).
    Li X; Ding Z; Wu Z; Xu Y; Yao H; Lin K
    Expert Opin Ther Pat; 2021 Aug; 31(8):723-743. PubMed ID: 33645365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on the recent advances in antifibrotic therapy.
    Tacke F; Weiskirchen R
    Expert Rev Gastroenterol Hepatol; 2018 Nov; 12(11):1143-1152. PubMed ID: 30261763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β.
    Edgley AJ; Krum H; Kelly DJ
    Cardiovasc Ther; 2012 Feb; 30(1):e30-40. PubMed ID: 21883991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting TGF-β Signaling in Kidney Fibrosis.
    Isaka Y
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30150520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence.
    Sandner P; Stasch JP
    Respir Med; 2017 Jan; 122 Suppl 1():S1-S9. PubMed ID: 28341058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting TGF-β signaling for the treatment of fibrosis.
    Györfi AH; Matei AE; Distler JHW
    Matrix Biol; 2018 Aug; 68-69():8-27. PubMed ID: 29355590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy for fibrotic diseases: nearing the starting line.
    Friedman SL; Sheppard D; Duffield JS; Violette S
    Sci Transl Med; 2013 Jan; 5(167):167sr1. PubMed ID: 23303606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.